Polyphenols, Iron, and the Real Question About Chelates

You probably do not need to separate polyphenol-rich foods or supplements from iron because you fear chronic iron depletion. In a meta-analysis of 34 randomized controlled trials, polyphenol supplements lowered some circulating iron measures but did not significantly lower ferritin, the main marker of stored iron. Hemoglobin rose instead.

That result runs against the familiar advice to treat tea, coffee, berries, cocoa, and other polyphenol sources as enemies of iron status. The advice began with real physiology: polyphenols can reduce non-heme iron absorption in a single meal. But a meal is not a year. Chronic iron balance reflects absorption, storage, red-blood-cell production, losses, and the body's regulatory response.

The more practical concern lies elsewhere: taking highly absorbable iron indefinitely without proving you need it. Ferrous bisglycinate chelate can correct iron deficiency effectively. Whether it remains safe during long-term self-prescribed use in iron-replete adults has barely been tested.

Single-meal absorption does not predict chronic iron depletion

Xu et al.'s 2021 systematic review and meta-analysis, registered prospectively on PROSPERO, pooled 34 randomized trials of dietary polyphenol supplementation. Across the overall analysis, serum iron fell by 13.72 μg/dL (95% confidence interval [CI], −20.74 to −6.71) and transferrin saturation fell by 3.10 percentage points (95% CI, −4.93 to −1.27). Those changes were statistically significant.

Ferritin did not change significantly: −9.34 ng/mL, with a 95% CI from −28.55 to +9.87 ng/mL. The interval crosses zero, so the analysis does not establish a reduction in iron stores. Meanwhile, hemoglobin increased by 8.53 g/L (95% CI, +3.33 to +13.73).

The healthy-participant subgroup tells the same practical story. Transferrin saturation declined by 3.83 percentage points (95% CI, −7.47 to −0.19), while hemoglobin rose by 12.87 g/L (95% CI, +1.61 to +24.14). Among participants with metabolic disease, serum iron fell by 8.60 μg/dL (95% CI, −16.10 to −1.10), while hemoglobin rose by 8.50 g/L (95% CI, +0.86 to +16.15).

Lower serum iron or transferrin saturation alone does not diagnose iron deficiency. These are circulating measures, not a direct inventory of stored iron. Stable ferritin plus higher hemoglobin does not fit a pattern of clinically meaningful iron depletion in these non-thalassemic groups.

A plausible explanation is not a proven mechanism

The pattern could reflect homeostasis. Chronic polyphenol exposure may modestly reduce iron moving through plasma, followed by compensatory changes in absorption or erythropoiesis. That is a reasonable interpretation of the endpoints, but it remains an interpretation. The meta-analysis did not measure hepcidin, intestinal transporters, fractional iron absorption, or the sequence of biological events that would prove the mechanism.

It also pooled different polyphenols, doses, trial durations, baseline iron status, and populations. The result answers a useful clinical question—whether supplementation depleted stores in the included groups—better than it answers whether every polyphenol product has identical effects.

The important exception: beta-thalassemia

Polyphenols are not neutral for every iron-regulation disorder. In the beta-thalassemia subgroup of the same analysis, serum iron fell by 23.19 μg/dL (95% CI, −35.84 to −10.55), ferritin fell by 223.62 ng/mL (95% CI, −359.32 to −87.91), and transferrin saturation fell by 3.23 percentage points (95% CI, −5.54 to −0.91). Hemoglobin did not change significantly.

That difference matters. Beta-thalassemia can involve iron loading and abnormal iron regulation, so a ferritin reduction may be clinically desirable rather than harmful. It also means that "polyphenols do not deplete iron" applies to healthy adults and the metabolic-disease populations in this evidence, not to every condition that affects iron metabolism. People with thalassemia, known iron overload, or other hematologic disease should not turn this finding into self-treatment.

Research on beta-thalassemia helps explain why iron regulation deserves respect. A review of ferroportin inhibition in beta-thalassemia describes how suppressed hepcidin can increase intestinal iron absorption and promote iron overload. In a 2025 randomized phase 2a study, Kattamis et al. evaluated the ferroportin inhibitor vamifeport in adults with non-transfusion-dependent beta-thalassemia. These disease-state studies establish the consequences of disrupted iron control; they do not show that a healthy person taking a supplement develops the same problem.

Bisglycinate works well for deficiency. Long-term use is the unknown.

Ferrous bisglycinate is often sold as gentle, natural, and better absorbed. The useful part of that marketing has clinical support: it can help correct deficiency. In an RCT of iron-deficient pregnant women, ferrous bisglycinate plus folinic acid increased mean hemoglobin from 10.38 ± 1.37 to 11.60 ± 1.21 g/dL (p < 0.001), improved ferritin, and reduced iron-deficiency anemia incidence versus the study controls.

Pregnancy is not a safety model for indefinite supplementation in iron-replete adults. Iron demand is unusually high, and hepcidin is already suppressed. A short-term trial designed to correct deficiency cannot tell us whether a person with normal iron status accumulates excess iron after years of use.

A 2025 randomized crossover absorption trial compared glycoprotein matrix-bound iron, ferrous bisglycinate chelate, and ferrous fumarate. The glycoprotein matrix product outperformed bisglycinate, and the three products produced different acute absorption profiles. Iron supplements are therefore not pharmacokinetically interchangeable. But the endpoint was acute serum iron response, not months or years of ferritin accumulation, and the study did not measure hepcidin sensitivity or identify the transporters responsible for absorption.

A 2025 two-person case series has described severe iron overload after more than four years of unsupervised bisglycinate use, including ferritin values of 2,194 ng/mL in a 15-year-old and 1,691 ng/mL in her mother. Neither reportedly had hereditary hemochromatosis, and both required monthly phlebotomy for one to two years. This is a signal, not proof of a general risk: two cases cannot estimate incidence or establish that bisglycinate caused the overload. Neither patient had baseline iron testing, and the adolescent's medication history adds another possible confounder.

The proposed explanation—that chelated iron may enter through pathways less constrained by ordinary iron regulation—is biologically plausible but unproven in healthy supplement users. Evidence that pathological free iron can appear when iron control fails comes from very different settings. For example, Essmann et al. studied 25 adults with ferritin above 1,000 μg/L undergoing myeloablative chemotherapy before stem-cell transplantation; deferasirox suppressed labile plasma iron in that extreme clinical context. It does not demonstrate supplement-induced overload.

Iron form may also affect the gut

Absorption is not the only difference among iron products. A secondary analysis of a double-blind randomized trial in Cambodian women found that oral iron supplementation altered gut microbial community structure in association with iron availability in the intestinal lumen. Finlayson-Trick et al. did not compare iron forms, so it cannot tell us whether bisglycinate has a better or worse microbiome effect than conventional salts. It does show that oral iron can affect more than blood tests.

What to do with this evidence

If you are healthy and iron-replete, avoid building your diet around fear that polyphenols will quietly drain your iron. The randomized evidence does not support that concern. If a clinician prescribed iron for documented deficiency, follow their instructions on timing with food, tea, coffee, or other supplements; treatment decisions differ from general dietary rules.

Use bisglycinate when there is a reason to correct iron deficiency, not as an indefinite wellness habit. Before starting long-term iron, confirm deficiency with appropriate testing. If you continue any oral iron product long term, checking ferritin and transferrin saturation annually is a sensible precaution, although the available evidence does not identify a formal guideline threshold specific to over-the-counter bisglycinate. Iron is essential. It is also one of the supplements most likely to punish the idea that more absorption is always better.